ANGPT2 and diabetic macular edema: In January 2022, the FDA approved Faricimab (Vabysmo, Roche/Genentech, Basel, Switzerland), a novel VEGF/angiopoietin-2 (Ang-2) bispecific agent for the treatment of nAMD and diabetic macular edema (DME).